Yıl: 2021 Cilt: 36 Sayı: 1 Sayfa Aralığı: 52 - 57 Metin Dili: İngilizce DOI: 10.5222/MMJ.2021.93902 İndeks Tarihi: 05-06-2021

Occult Adrenal Insufficiency in Renal Amyloidosis Patients

Öz:
Objective: Systemic amyloidosis may affect many organs, and may cause endocrinologic problems which may result in adrenal insufficiency. However, assessment of adrenocortical reserve is challenging in amyloidosis patients with renal involvement. We aimed to evaluate adrenocortical reserve with various methods of cortisol measurement to determine any occult clinical condition.Methods: Patients with renal amyloidosis and healthy subjects were evaluated in this cross-sectional study. Basal cortisol, corticosteroid-binding globulin (CBG), and albumin levels were measured. Serum free cortisol (cFC) level was calculated. Cortisol response tests performed after ACTH stimulation test (250 μg, intravenously) were evaluated, and free cortisol index (FCI) was calculated.Results: Twenty renal amyloidosis patients, and 25 healthy control subjects were included in the study. Patients and control subjects had similar median serum baseline cortisol levels [258 (126-423) vs 350 (314-391) nmol/L, p=0.169)] whereas patients’ stimulated cortisol levels at the 60th minute were lower [624 (497-685) vs 743 (674-781) nmol/L, p=0.011)]. The 60th-minute total cortisol levels of 8 of the 20 (40%) amyloidosis patients were <500 nmol/L, but only three of these 8 patients had stimulated FCI <12 nmol/mg suggesting an adrenal insufficiency (15%).Conclusion: ACTH stimulation test and cortisol measurements should be considered in renal amyloidosis patients with severe proteinuria to avoid false positive results if only ACTH stimulation test is used. It will be appropriate to evaluate this group of patients together with estimated measurements as FCI.
Anahtar Kelime:

Renal Amiloidoz Hastalarında Gizli Adrenal Yetmezlik

Öz:
Amaç: Sistemik amiloidoz birçok organı etkileyebilir ve adrenal yetmezlikle sonuçlanabilecek endokrinolojik problemlere sebep olabilir. Renal tutulumlu amiloidoz hastalarında ise adrenokortikal rezervi değerlendirmek zordur. Biz bu çalışmada farklı kortizol ölçüm yöntemleri ile renal tutulumlu amiloidoz hastalarında gizli adrenal problemlerini tespit etmeyi planladık. Yöntem: Bu kesitsel çalışmada renal tutulumu olan amilodoz hastalarını ve sağlıklı kontrol grubunu adrenal yetmezlik testleri açısından değerlendirdik. Bazal kortizol ve kortizol bağlayıcı globulin (KBG) ölçüldü. Serum serbest kortizol düzeyi hesaplandı. 250 mcg ACTH stimulasyon testi sonrası kortizol yanıt testleri değerlendirildi ve serbest kortizol indeksi (SKI) hesaplandı. Bulgular: Çalışmaya 20 amilodoz hastası ve 25 sağlıklı kontrol grubu dahil edildi. Bazal serum kortizol düzeyleri hasta ve kontrol grubunda benzerdi [258 (126-423) vs 350 (314-391) nmol/L, p=0.169)]. Ancak amiloidoz grubunda ACTH stimulasyon testi sonrası 60. dk. kortizol yanıtı daha düşüktü [624 (497-685) vs 743 (674-781) nmol/L, p=0.011)]. 20 hastanın 8’inde (40%) bu değer <500 nmol/L olarak bulundu. Ancak sadece bu sekiz hastanın üçünde (15%) SKI <12 nmol/mg olarak bulundu. Bu üç hasta klinik olarak da adrenal yetmezlikle uyumlu olabilecek bulgular taşıyordu. Sonuç: Ağır proteinürisi olan renal tutulumlu amiloidoz hastalarında, adrenal yetmezlik araştırılırken sadece ACTH stimulasyon testinin kullanılması yanlış pozitifliklere sebep olabilir. Bu grup hastaları SKI gibi hesaplanmış ölçümlerle birlikte değerlendirmek daha uygun olacaktır.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Pinney JH, Lachmann HJ. Systemic AA amyloidosis. Subcell Biochem. 2012;65:541-64. [CrossRef]
  • 2. Ogawa S, Murakami T, Inoshima Y, Ishiguro N. Effect of heating on the stability of amyloid A (AA) fibrils and the intra- and cross-species transmission of AA amyloidosis. Amyloid. 2015;22:236-43. [CrossRef]
  • 3. Emeksiz H, Bakkaloglu S, Camurdan O, et al. Acute adrenal crisis mimicking familial Mediterranean fever attack in a renal transplant FMF patient with amyloid goiter. Rheumatol Int. 2010;30:1647-9. [CrossRef]
  • 4. Chanson P, Guignat L, Goichot B, et al. Consensus Group 2: Adrenal insufficiency: screening methods and confirmation of diagnosis. Annales d’Endocrinologie. 2017;78:495-511. [CrossRef]
  • 5. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:364-89. [CrossRef]
  • 6. le Roux CW, Sivakumaran S, Alaghband-Zadeh J, Dhillo W, Kong WM, Weheeler MJ. Free cortisol index as surrogate marker for serum free cortisol. Ann Clin Biochem. 2002;39:406-8. [CrossRef]
  • 7. Bourne RS, Webber SJ, Hutchinson SP. Adrenal axis testing and corticosteroid replacement therapy in septic shock patients--local and national perspectives. Anaesthesia. 2013;58:591-6. [CrossRef]
  • 8. Coolens JL, Van Baelen H, Heyns W. Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. J. Steroid Biochem. 1987;26:197-202. [CrossRef]
  • 9. Dhillo WS, Kong WM, Le Roux CW, et al. Cortisol binding globulin is important in the interpretation of dynamic tests of the hypothalamic-pituitary-adrenal axis. Eur J Endocrinol. 2002;146:231-5. [CrossRef]
  • 10. Brennan A, O’Connor KA, Plant WD, O’Halloran DJ. Nephrotic syndrome: cause of an abnormal response to the rapid ACTH stimulation test. Nephrol Dial Transplant. 2004;19:477-8. [CrossRef]
  • 11. Tait JF, Burstein S. In vivo studies of steroid dynamics in man. In: Pincus V, Thimann KV, Astwood EB, editors. The Hormones (5). New York: Academic Press; 1964. p. 441-557. [CrossRef]
  • 12. Brien TG. Human corticosteroid binding globulin. Clin Endocrinol (Oxf). 1981;14:193-212. [CrossRef]
  • 13. Emptoz-Bonneton A, Cousin P, Seguchi K, et al. Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000;85:361-7. [CrossRef]
  • 14. Gagliardi L, Ho JT, Torpy DJ. Corticosteroid-binding globulin: the clinical significance of altered levels and heritable mutations. Mol Cell Endocrinol. 2010;316:24-34. [CrossRef]
  • 15. Davidson JS, Bolland MJ, Croxson MS, Chiu W, Lewis JG. A case of low cortisol-binding globulin: Use of plasma free cortisol in interpretation of hypothalamic-pituitary-adrenal axis tests. Ann Clin Biochem. 2006;43:237-9. [CrossRef]
  • 16. le Roux CW, Chapman GA, Kong WM, Dhillo WS, Jones J, Alaghband-Zadeh J. Free cortisol index is better than serum total cortisolin determining hypothalamic-pituitary-adrenal status in patients undergoing surgery. J Clin Endocrinol Metab. 2003;88:2045-8. [CrossRef]
  • 17. Danby P, Harris KP, Williams B, Feehally J, Walls J. Adrenal dysfunction in patients with renal amyloid. Q J Med. 1990;76:915-22. PMID: 2236477.
  • 18. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med. 2003;31:141-5. [CrossRef]
  • 19. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348:727-34. [CrossRef]
  • 20. Arafah BM. Hypothalamic-pituitary adrenal function during critical illness: Limitations of current assessment methods. J Clin Endocrinol Metab. 2006;91:3725-45. [CrossRef]
  • 21. Ho JT, Al-Musalhi H, Chapman MJ, et al. Septic shock and sepsis: A comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab. 2016;91:105-14. [CrossRef]
  • 22. Annane D, Maxime V, Ibrahim F, Alvarez JC, Abe E, Boudou P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med. 2006;174:1319-26. [CrossRef]
APA TURGUT D, Piskinpasa s, Keskin H, Ağbaht K, Coskun yenigun E, DEDE F (2021). Occult Adrenal Insufficiency in Renal Amyloidosis Patients. , 52 - 57. 10.5222/MMJ.2021.93902
Chicago TURGUT DİDEM,Piskinpasa serhan,Keskin Havva,Ağbaht Kemal,Coskun yenigun Ezgi,DEDE FATIH Occult Adrenal Insufficiency in Renal Amyloidosis Patients. (2021): 52 - 57. 10.5222/MMJ.2021.93902
MLA TURGUT DİDEM,Piskinpasa serhan,Keskin Havva,Ağbaht Kemal,Coskun yenigun Ezgi,DEDE FATIH Occult Adrenal Insufficiency in Renal Amyloidosis Patients. , 2021, ss.52 - 57. 10.5222/MMJ.2021.93902
AMA TURGUT D,Piskinpasa s,Keskin H,Ağbaht K,Coskun yenigun E,DEDE F Occult Adrenal Insufficiency in Renal Amyloidosis Patients. . 2021; 52 - 57. 10.5222/MMJ.2021.93902
Vancouver TURGUT D,Piskinpasa s,Keskin H,Ağbaht K,Coskun yenigun E,DEDE F Occult Adrenal Insufficiency in Renal Amyloidosis Patients. . 2021; 52 - 57. 10.5222/MMJ.2021.93902
IEEE TURGUT D,Piskinpasa s,Keskin H,Ağbaht K,Coskun yenigun E,DEDE F "Occult Adrenal Insufficiency in Renal Amyloidosis Patients." , ss.52 - 57, 2021. 10.5222/MMJ.2021.93902
ISNAD TURGUT, DİDEM vd. "Occult Adrenal Insufficiency in Renal Amyloidosis Patients". (2021), 52-57. https://doi.org/10.5222/MMJ.2021.93902
APA TURGUT D, Piskinpasa s, Keskin H, Ağbaht K, Coskun yenigun E, DEDE F (2021). Occult Adrenal Insufficiency in Renal Amyloidosis Patients. Medeniyet Medical Journal, 36(1), 52 - 57. 10.5222/MMJ.2021.93902
Chicago TURGUT DİDEM,Piskinpasa serhan,Keskin Havva,Ağbaht Kemal,Coskun yenigun Ezgi,DEDE FATIH Occult Adrenal Insufficiency in Renal Amyloidosis Patients. Medeniyet Medical Journal 36, no.1 (2021): 52 - 57. 10.5222/MMJ.2021.93902
MLA TURGUT DİDEM,Piskinpasa serhan,Keskin Havva,Ağbaht Kemal,Coskun yenigun Ezgi,DEDE FATIH Occult Adrenal Insufficiency in Renal Amyloidosis Patients. Medeniyet Medical Journal, vol.36, no.1, 2021, ss.52 - 57. 10.5222/MMJ.2021.93902
AMA TURGUT D,Piskinpasa s,Keskin H,Ağbaht K,Coskun yenigun E,DEDE F Occult Adrenal Insufficiency in Renal Amyloidosis Patients. Medeniyet Medical Journal. 2021; 36(1): 52 - 57. 10.5222/MMJ.2021.93902
Vancouver TURGUT D,Piskinpasa s,Keskin H,Ağbaht K,Coskun yenigun E,DEDE F Occult Adrenal Insufficiency in Renal Amyloidosis Patients. Medeniyet Medical Journal. 2021; 36(1): 52 - 57. 10.5222/MMJ.2021.93902
IEEE TURGUT D,Piskinpasa s,Keskin H,Ağbaht K,Coskun yenigun E,DEDE F "Occult Adrenal Insufficiency in Renal Amyloidosis Patients." Medeniyet Medical Journal, 36, ss.52 - 57, 2021. 10.5222/MMJ.2021.93902
ISNAD TURGUT, DİDEM vd. "Occult Adrenal Insufficiency in Renal Amyloidosis Patients". Medeniyet Medical Journal 36/1 (2021), 52-57. https://doi.org/10.5222/MMJ.2021.93902